Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01026220 · OUTCOME

Second-event-free Survival

Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma · Source last updated 2022-04-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Probability of survival
Interval / dispersion
95% Confidence Interval
Time frame
At 4 years from enrollment

What was measured

Second event here is defined as any relapse/progression of Hodgkin Lymphoma (HL) or a previously reported second malignant neoplasm (SMN), a new SMN, or death after a first event which can be relapse/progression of HL, SMN, biopsy-proven HL following completion of Consolidation for Slow Early Response (SER) patient, positive bilateral bone marrow biopsy following completion of Consolidation for Stage IV patient, or death. If death occurs as the 1st event, it also counts as the 2nd event.

Analysis population: This analysis excludes n=20 patients who had protocol early terminations or deviations (n=4 Regimen I, n=12 Regimen II, and n=4 Induction only).

Groups in this outcome

Group 1

All Patients

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Group 1145

Reported measurements

Source class 1
Values in Probability of survival · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Group 10.91Not reported0.850.95Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0.85
        upper Limit
        0.95
        value
        0.91
denoms
  1. counts
    1. group Id
      OG000
      value
      145
    units
    Participants
description
Second event here is defined as any relapse/progression of Hodgkin Lymphoma (HL) or a previously reported second malignant neoplasm (SMN), a new SMN, or death after a first event which can be relapse/progression of HL, SMN, biopsy-proven HL following completion of Consolidation for Slow Early Response (SER) patient, positive bilateral bone marrow biopsy following completion of Consolidation for Stage IV patient, or death. If death occurs as the 1st event, it also counts as the 2nd event.
dispersion Type
95% Confidence Interval
groups
  1. description
    All Patients
    id
    OG000
    title
    Group 1
param Type
NUMBER
population Description
This analysis excludes n=20 patients who had protocol early terminations or deviations (n=4 Regimen I, n=12 Regimen II, and n=4 Induction only).
reporting Status
POSTED
time Frame
At 4 years from enrollment
title
Second-event-free Survival
type
PRIMARY
unit Of Measure
Probability of survival

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice